Serum SDF-1α not only differentiated AML patients from controls with notable accuracy (AUC of 0.76), but also emerged as a predictive marker for chemotherapy outcomes, with higher levels correlating with NCR and shorter overall survival. Here, CXCL12 is linked to acute myeloid leukemia.